Schrödinger Inc. has paired up with Zai Lab Ltd. to collaborate on an oncology program targeting DNA damage response (DDR) in a deal that could net Schrödinger up to $338 million.
Burning Rock Biotech Ltd. has formed a global strategic partnership with Impact Therapeutics Inc. to develop companion diagnostics for a pipeline of drugs in the field of synthetic lethality.
Positive top-line data from Beyondspring Inc.’s phase III study of plinabulin combined with docetaxel to treat second- and third-line non-small-cell lung cancer (NSCLC) compared to docetaxel alone propelled the company value dramatically higher Aug. 4.
Antengene Corp. Ltd. has gained the first greenlight in Asia for the oral exportin 1 (XPO1) inhibitor selinexor, in-licensed from Karyopharm Therapeutics Inc., after South Korea’s Ministry of Food and Drug Safety gave the thumbs up for its NDA. The drug has been approved in Korea to treat relapsed or refractory multiple myeloma (MM) and relapsed and refractory diffuse large B-cell lymphoma (DLBCL) in combination with dexamethasone.
Zentera Therapeutics Inc. completed a $75 million series B financing round to help further its candidates in China, as it paves the way for a listing in Hong Kong next year.
Eli Lilly and Co. has established a multiyear collaboration with Kumquat Biosciences Inc. for the discovery, development and commercialization of new small molecules for stimulating tumor-specific immune responses. Kumquat will receive $70 million up front, including an equity investment, and is eligible for more than $2 billion in potential milestone payments plus royalties on any marketed products.
Another shoe dropped on Oncopeptides AB when the U.S. FDA issued an alert July 28 citing trial data showing an increased risk of death with the company’s only marketed drug, Pepaxto, used in combination with dexamethasone to treat multiple myeloma. The agency said it’s continuing to evaluate the Ocean trial results and may hold a public meeting to discuss the safety findings and explore the continued marketing of Pepaxto (melphalan flufenamide), which was granted accelerated approval in February as a fifth-line treatment for relapsed or refractory multiple myeloma.
Amgen Inc. will pay $900 million in cash to acquire privately held Teneobio Inc. In exchange for the cash, Amgen gets all of Teneobio’s outstanding shares, which could end up paying out quite a bit as contingent milestone payments to Teneobio’s equity holders could be worth up to $1.6 billion.
LONDON – Artios Ltd. has closed a $153 million series C, positioning it to intensify clinical development of its two lead programs, whilst applying its DNA damage response platform to exploit the full spectrum of vulnerabilities presented by inhibition of DNA damage repair enzymes.
New data on the addition of Infinity Pharmaceuticals Inc.'s oral PI3K-gamma inhibitor, eganelisib, to PD-(L)1 in both urothelial and triple-negative breast cancer patients appeared to evidence benefits for the combination. Benefit for company shares (NASDAQ:INFI), however, was nowhere to be seen, as they fell 31.5% to $1.52 on July 27. In a same-day earnings report, the Cambridge, Mass.-based company said it had a cash balance of $97.3 million to fund further development of the drug and filed to raise the maximum amount of capital it may raise in future sales of its shares.
RSS
